XFOR READ THE FULL XFOR RESEARCH REPORT Business Update Full Enrollment of Phase 3 4WARD Trial Expected in 2H25 X4 ...
TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the first patient in Cohort 4 of its ...
First patient in Cohort four has been treated with TTX-MC138 Ten patients have been treated with TTX-MC138 at escalating dose levels Additional patients being evaluated ...
Investigate the science behind red light therapy and its effects on skin rejuvenation, sleep quality, and muscle recovery in ...
Although itolizumab did not improve response rates at Day 29 for patients with acute GVHD, the therapy showed significant ...
Successful End-of-Phase 2 Meeting with FDA Results in Alignment on Phase 3 Plans for CLS-AX in Wet AMD - - Asia-Pacific Partner's New Drug Application for ARCATUS® (XIPERE®) for Uveitic Macular Edema ...
17h
Study Finds on MSNBrain Changes Linger Long After Concussed Athletes Are Cleared to PlayIn a nutshell Being symptom-free doesn’t mean the brain has fully healed. Even after athletes are medically cleared to return ...
15hon MSNOpinion
Ending clinical trials with no warning can put patients at risk.
Cancer screening tests can be divided into early detection and preventive tests.1 Early-detection tests (eg, mammography for ...
21h
Medpage Today on MSNNew Frontiers at ACC Meeting: Semaglutide, INOCA, & MoreCHICAGO -- Coming this weekend, the American College of Cardiology (ACC) annual conference will feature research exploring ...
Population-based cancer registries are the benchmark for assessing a country's cancer burden.1 Cancer registries across the globe play a crucial role in providing valuable data1 for monitoring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results